Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,064 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T, Sesoko S, Woerle HJ, Dugi KA. Sarashina A, et al. Among authors: taniguchi a. Drug Metab Pharmacokinet. 2013;28(3):213-9. doi: 10.2133/dmpk.dmpk-12-rg-082. Epub 2012 Nov 13. Drug Metab Pharmacokinet. 2013. PMID: 23149871 Free article. Clinical Trial.
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Watada H, Yamauchi T, Yamamoto F, Taniguchi A, Yarush L, Heilmann C, Yasui A. Watada H, et al. Among authors: taniguchi a. Expert Opin Drug Saf. 2020 Sep;19(9):1193-1202. doi: 10.1080/14740338.2020.1782884. Epub 2020 Jul 2. Expert Opin Drug Saf. 2020. PMID: 32552153
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA. Horie Y, et al. Among authors: taniguchi a. Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2. Clin Ther. 2011. PMID: 21723606 Clinical Trial.
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.
Higaki J, Komuro I, Shiki K, Ugai H, Taniguchi A, Ikeda H, Kuroki D, Nishimura S, Ogihara T. Higaki J, et al. Among authors: taniguchi a. Hypertens Res. 2017 Jan;40(1):51-60. doi: 10.1038/hr.2016.100. Epub 2016 Sep 1. Hypertens Res. 2017. PMID: 27581533 Free PMC article. Clinical Trial.
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA. Sarashina A, et al. Among authors: taniguchi a. Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004. Clin Ther. 2010. PMID: 20637971 Clinical Trial.
Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study.
Higaki J, Komuro I, Shiki K, Lee G, Taniguchi A, Ikeda H, Kuroki D, Nishimura S, Ogihara T. Higaki J, et al. Among authors: taniguchi a. Hypertens Res. 2017 Mar;40(3):251-258. doi: 10.1038/hr.2016.124. Epub 2016 Oct 20. Hypertens Res. 2017. PMID: 27761000 Free PMC article. Clinical Trial.
1,064 results